Decoy Therapeutics Inc. — Form 10-Q
Filed November 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 78/100
What the filing says
Decoy Therapeutics issued a warrant to Armistice Capital Master Fund Ltd. to purchase 2,368,868 shares of common stock at an exercise price of $3.25 per share. The warrant becomes exercisable September 23, 2026, and expires five years later (September 23, 2031). The warrant includes standard provisions for cashless exercise, anti-dilution adjustments, and fundamental transaction protections. No cash was paid disclosed in this exhibit; the warrant appears tied to an 'Inducement Letter' referenced but not detailed here.
Why this rating
Warrant grants 2.37M shares (potential dilution ~124× current $1.9M market cap if all exercised at $3.25 = ~$7.7M proceeds). Significant dilution and potential future capital, but delayed exercise date (Sept 2026) and favorable anti-dilution terms for holder suggest meaningful refinancing risk/opportunity. Material for micro-cap but not immediate crisis.
Price action (we called it neutral)
before filing · preread $1.05 ▼ 0.00% | at our read · unknown $1.05 | +10 min · unknown $1.05 ▲ 0.00% | +30 min · unknown $0.99 ▼ 6.16% | +1 hr · unknown $1.00 ▼ 5.21% | +4 hrs · unknown $0.97 ▼ 8.06% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.